Durvalumab boosts survival for small-cell lung cancer but at a high cost
A new cost/benefit analysis of an immunotherapy drug that showed significantly longer survival for people with an aggressive form of lung cancer, called small-cell lung cancer, concludes that the treatment might be too expensive to be worth it.
